SCHEMBL256823

SCHEMBL256823

Cc1cccc(C(=O)Cc2ccc(F)cc2)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
KDM4E B2RXH2 4/20 0.50
MAPT P10636 3/20 0.50
TP53 P04637 3/20 0.50
HTT P42858 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
XBP1 P17861 1/20 0.47
HIF1A Q16665 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
CNR2 P34972 2/20 0.43
GAA P10253 1/20 0.42
P2RX7 Q99572 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468225 0.85 SMN1; SMN2 (0.51) LMNAKDM4ETP53KMT2AMEN1
SCHEMBL256855 0.83 SMN1; SMN2 (0.53) LMNAKDM4EMAPTTP53HTT
SCHEMBL28799843 0.76 LMNA (0.54) LMNAKDM4EMAPTTP53HTT
SCHEMBL15902289 0.76 BRPF1 (0.61) LMNAKDM4EMAPTTP53HTT
SCHEMBL7811204 0.75 TP53 (0.64) LMNAKDM4EMAPTTP53HTT
SCHEMBL8956100 0.73 LMNA (0.51) LMNAKDM4EMAPTTP53HTT
SCHEMBL11620182 0.73 LMNA (0.51) LMNAKDM4EMAPTTP53HTT
SCHEMBL30578286 0.73 ESR1 (0.46) LMNAKDM4ETP53HTTKMT2A
SCHEMBL10770139 0.73 ESR1 (0.46) LMNAKDM4ETP53HTTKMT2A
SCHEMBL581465 0.73 ESR1 (0.46) LMNAKDM4ETP53HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 LMNA 1477/4885KDM4E 2413/4885MAPT 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.